Servier Frees Edgewise for Cardio Mission with $2.65B Muscular Dystrophy Deal

Why It Matters

The acquisition gives Servier a late‑stage rare‑disease asset that could become the first approved therapy for Becker muscular dystrophy, while providing Edgewise with non‑dilutive capital to accelerate its cardio‑vascular programs.

Key Takeaways

• Servier acquires Edgewise's muscular dystrophy unit for up to $2.65 B.
• $1.55 B paid upfront, $1.1 B in milestones.
• Sevasemten moves to Servier; Edgewise refocuses on cardiovascular pipeline.
• Edgewise shares jump >15% to $39.53 after deal announcement.
• Phase 3 GRAND CANYON trial for Becker MD proceeds under Servier.

Pulse Analysis

Servier’s purchase of Edgewise Therapeutics’ muscular‑dystrophy business marks the French group’s second multibillion‑dollar rare‑disease deal this year, following the $2.5 billion acquisition of Day One Biopharmaceuticals. By paying $1.55 billion upfront and committing up to $1.1 billion in milestones, Servier deepens its neurology portfolio while reinforcing its broader focus on oncology, neurology and cardiometabolic therapies. The transaction also signals a growing appetite among large European pharma to secure late‑stage assets that can complement existing pipelines and provide a foothold in high‑unmet‑need indications such as Becker and Duchenne muscular dystrophy.

The centerpiece of the deal is sevasemten, a fast skeletal‑myosin inhibitor currently in a Phase 3 “GRAND CANYON” trial for Becker muscular dystrophy and a Phase 2 study for Duchenne. If approved, sevasemten would become the first therapy specifically indicated for Becker, a market projected to generate up to $1 billion in peak sales worldwide. Servier inherits the regulatory risk and the data presented at the 2026 Muscular Dystrophy Association meeting, which suggested functional gains. By absorbing the clinical program, Servier can allocate resources to accelerate filing timelines and potentially capture a first‑in‑class premium.

With the muscular‑dystrophy assets sold, Edgewise redirects its capital toward cardiovascular candidates, notably EDG‑7500 for hypertrophic cardiomyopathy and EDG‑15400 for heart‑failure with preserved ejection fraction. The $2.65 billion cash infusion funds Phase 2 “CIRRUS‑HCM” read‑out and paves the way for a Phase 3 launch later this year. Analysts have praised the non‑dilutive financing, noting a 15 % share rally to $39.53. The move also cleans the balance sheet, positioning Edgewise as an attractive acquisition target for firms seeking to broaden their cardio‑vascular pipeline.